VOL. XCIV, NO. 247
* WIDE MOAT STOCKS COMPARISON *
NO ADVICE
Sunday, December 28, 2025
Stock Comparison
Bristol-Myers Squibb Company vs Manhattan Associates, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Bristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Manhattan Associates, Inc.
MANH · The Nasdaq Stock Market LLC
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Side-by-side metrics
Moat coverage
Shared moat types
Bristol-Myers Squibb Company strengths
Manhattan Associates, Inc. strengths
Segment mix
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Manhattan Associates, Inc. segments
Full profile >Cloud subscriptions (Manhattan Active SaaS)
Oligopoly
Professional services (implementation, consulting, training)
Competitive
Maintenance and support (legacy perpetual licenses)
Monopoly
Perpetual licenses and hardware
Competitive
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.